References
- Nemeroff CB. Neuroendocrinology. In New Oxford Textbook of Psychiatry, MG Gelder, Juan J. Lopez- Ibor Jr, Nancy C. Andreasen (editors). New York: Oxford University Press; 2004. p. 181–8.
- Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Prevalence of hyperprolactinemia in schizophrenic patients treated with convencional antipsychotic medications or risperidone. Psychoneuroendocrinology 2003;28(2):55–68. [CroosRef]
- Torre DL, Falorni A. Pharmacologicalcauses of hyperprolactinemia. Therapeutics and Clinical Risk Management 2007;3(5):929–51.
- Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinemia. Drugs 2004;64(20):2291–314. [CroosRef]
- Ajmal A, Joffe H, Nachtigall LB. Psychotropic-Induced Hyperprolactinemia: A Clinical Review. Psychosomatics 2014;55(1):29–36. [CroosRef]
- Cetin M, Turgay A. Antipsychotic Treatment In The Fiftieth Year of Modern Psychopharmacology: An Update Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology 2002;12(4):211–26. (Turkish)
- Uzun Ö, Özşahin A, Özmenler KN, Doruk A, Battal S. Clozapine In Treatment-Resistant Schizophrenia: followed-up Study for Three Years. Klinik Psikofarmokoloji Bülteni-Bulletin of Clinical Psychopharmacology 2000;10(2):74–80. (Turkish)
- Molitch ME. Medication-induced hyperprolactinemia. Mayo Clinic Proceedings 2005;80(8):1050–7. [CroosRef]
- Knegtering R, Baselmans P, Castelein S, Bosker F, Bruggeman R, van den Bosch R. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry 2005;162(5):1010–2. [CroosRef]
- Lee BH, Kim YK, Park SH. Using aripiprazole to resolve antipsychotic induced symptomatic hiperprolactinemia: a pilot study. ProgNeuropsychopharmacol Biol Psychiatry 2006;30(4):714–7. [CroosRef]
- Fitzgerald P, Dinan TG. Prolactin and dopamine: What is the connection? A Review. J Psychopharmacology 2008;22(Suppl.2):12–9. [CroosRef]
- Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC. Prolactinlevels in male schizophrenic patients treated with risperidone and haloperidol: a double-blind and randomized study. Psychopharmacology 2005;178(1):35–40. [CroosRef]
- Goodnick PJ, Rodriguez L, Santana O. Antispychotics: impact on prolactin levels. Expert Opin Pharmacother 2002;3(10):1381–91. [CroosRef]
- Erbinç S, Semiz ÜB, Başoğlu C, Çetin M, Baykız AF, Kandilcioğlu H, et al. Efficacy and safety of amisülpride treatment in schizophrenia:comparison with haloperidol. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology 2004;14(3):143–9. (Turkish)
- Muench J, Hamer AM. Adverse Effects of Antipsychotic Medications. American Family Physician 2010;81(5):617–22.
- Taylor DM. Aripiprazole: A review of its pharmacology and clinical use. Int J Clin Pract 2003;57(1):49–54.
- Kuloğlu M, Ekinci O, Albayrak Y, Çayköylü A. Aripiprazole treatment in the patients who developed symptomatic hyperprolactinemia associated with antipsychotic use:a case series. Anadolu Psikiyatri Dergisi 2009;10(1):66–7. (Turkish)
- Basterreche N, Zumarraga M, Aurora A, Olivas O, Davila W. Aripiprazole reverses Paliperidone-induced Hyperprolactinemia. Actas Esp Psiquiatr 2012;40(5):90–2.
- Xianbin Li, Yilang Tang, Chuanyue Wang. Adjunctive Aripiprazole Versus Placebo for Antipsychotic Induced Hyprolactinemia Meta Analysis of Randomized Controlled Trials. Plos One 2013;8(8):e70179. [CroosRef]
- Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. Journal of Pharmacology and Experimental Therapeutics 2002;302(1):381–9. [CroosRef]